Lv3
210 积分 2025-05-29 加入
In vivo CAR T cell engineering: design principles and open questions
9天前
已完结
In vivo chimeric antigen receptor (CAR)-T cell therapy
24天前
已完结
In vivo CAR T cell engineering: design principles and open questions
24天前
已完结
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
1个月前
已完结
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
3个月前
已完结
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
3个月前
已完结
Antigen experience history directs distinct functional states of CD8+ CAR T cells during the antileukemia response
3个月前
已完结
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps
4个月前
已完结
GPCR drug discovery: new agents, targets and indications
5个月前
已完结
Targeting protein disorder: the next hurdle in drug discovery
5个月前
已完结
皖公网安备34019202002308
